Clinical trials to investigate whether the combination therapy of IGMKK16E7 and anti-CTLA4 antibody has antitumor effects against invasive cervical cancer and other HPV-related cancers will be considered in the future, as will efforts to establish additional predictive biomarkers that allow personalized therapy with IGMKK16E7. Here, CTLA4 is linked to cervical carcinoma.